ClinicalTrials.gg
RecruitingNCT05398094MERIT-lungUpdated Apr 30, 2026

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

A Phase 2 interventional study of Sotorasib in Non-small Cell Lung Cancer Stage III and KRAS P.G12C, sponsored by Fundación GECP. Recruiting at 20 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Fundación GECP · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 10 under way, 1 of them phase 3. sotorasib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
12th of 19
19 · median 24
Started
2022
with 8 others
Phase 2
10 of 19
4 open now
Registered
9th of 19
by date
Lead sponsor
1 of 19
Fundación GECP

Among the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by planned enrollment, is one of 9 that started in 2022, is one of 10 in phase 2, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sotorasib

sotorasib: first FDA approval 2021 (LUMAKRAS), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 months.

Read the detailed description

This is an open-label, non-randomized, exploratory, phase II multi-centre clinical trial.The total sample size is 43 patients. The population to be included are unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients.

Patients randomised will receive AMG510 (Sotorasib) 960mg once daily for 2 cycles (Q4W) in the induction phase and AMG510 (Sotorasib) 960 mg once daily (Q4W) in the treatment post-induction phase. Treatment post-induction phase only for patients with SD, PR or CR after induction treatment. This treatment will be administered until progression disease (PD), unacceptable toxicity, patient or physician's decision to discontinue or death.

The primary objective is to assess the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 (PFS12) months according to Response Evaluation Criteria in Solid Tumors (RECIST) version PFS are defined as the time from inclusion until objective tumor progression or death.

Patient accrual is expected to be completed within 5 years and a half, treatment is planned to extend for 1.5 years and the patients will be followed up for 2 years. The study will end once survival follow-up has concluded.

03

Conditions studied

  • Non-small Cell Lung Cancer Stage III
  • KRAS P.G12C

Keywords

  • Sotorasib
  • Unresectable
  • Chemo-radiotherapy
  • Lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female, aged ≤ 80 years old
  • 2. performance status of 0-1
  • 3. or cytologically confirmed, unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology.
  • 4. Patients who have documentation of KRAS p.G12C prior to enrollment. This determination can be done either by solid or liquid .
  • 5. No prior treatment for unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC.
  • 6. Having a ≥ 12 weeks
  • 7. Patients must be ineligible for concurrent chemo-radiotherapy because of:

    1. Tumor size ≥ 5 cm and lymph node N2 involvement
    2. The target lesion has to be bulky disease and/or more than 35% of the total volume of the two lungs should receive more than 20 Gy (V20) or inadequate pulmonary function
    3. Interstitial Lung diseases
    4. Prior treatment with thoracic radiotherapy for any reason
    5. Or under decision of a tumor committee as inappropriate due to local characteristics to perform treatment upfront
  • 8. PET-CT at baseline is mandatory to confirm the absence of distant disease and to confirm unresectable disease
  • 9. PET-CT positive mediastinic adenopathies must be histologically confirmed. Mediastinic involvement could be considered without histological test when no margin can be distinguished in the lymph node mass.
  • 10. Brain CT or MRI is mandatory
  • 11. Patients with at least 1 , as defined by v1.1.
  • 12. Adequate hematologic and organ function.
  • 13. All patients are notified of the nature of this study and signed a written in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.
  • 14. Willingness and ability to comply with scheduled visits and study procedures
  • 15. For female patients of , a negative pregnancy test must have been documented prior to enrollment (within 14 days prior to enrollment).
  • 16. For female patients of childbearing potential, agreement (by patient and/or partner) to usea highly effective form(s) of that results in a low failure rate (\< 1% per year)when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib). No hormonal methods and preferably barrier method always containing a spermicide, intrauterine device (IUD): intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.
  • 17. For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception that results in a low failure rate [\< 1% per year] when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib).
  • 18. Women who are not (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to enrollment.
  • 19. must be ≤ 470 msec in females and ≤ 450 msec in males, based on the average obtained from three .

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with a known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene, ALK translocations or ROS1 mutations
  • 2. Weight loss >10% within the previous 3 months
  • 3. Patients with uncontrolled neuropathy (sensory) grade 2 or greater regardless of cause according to v5.0
  • 4. Major surgery within 28 days of study day 1
  • 5. Significant gastrointestinal disorder that results in significant malabsorption, requirement for intravenous alimentation, or inability to take oral medication
  • 6. Significant cardiovascular disease, such as cardiac disease (ClassII or greater), myocardial infarction within 6 months prior to study day 1, unstable arrhythmias or unstable angina
  • 7. Ongoing cardiac dysrhythmias of CTCAE grade ≥2, uncontrolled atrial fibrillation of any grade or interval > 470ms
  • 8. Severe infections within 4 weeks prior to randomization including, but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia
  • 9. Therapeutic oral or intravenous antibiotics within 2 weeks prior to randomization
  • 10. Patients with any concomitant and uncontrolled medical disorder
  • 11. Patients with vena cava syndrome
  • 12. Malignant pleural or pericardial effusion: both will be considered as suggestive of metastaticdisease. Also, are excluded those with negative cytology but being exudates. Patients with non-visible by thoracic X-ray pleural effusion or too small to be safely punctured could be included.
  • 13. Prior treatment with anti-neoplasic drugs
  • 14. other than NSCLC within 3 years prior to enrollment
  • 15. Women who are pregnant, lactating, or intending to become pregnant during the study.
  • 16. Positive test for . All patients will be tested for HIV prior to inclusion into the study; patients who test positive for HIV will be excluded from the clinical study.
  • 17. Patients with active or .
  • 18. Active tuberculosis.
  • 19. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.
  • 20. Patients with illnesses or conditions that interfere with their capacity to understand follow and/or comply with study procedures.
  • 21. Known or suspected to drugs with similar chemical structures to the study drug
  • 22. Evidence of any other disorder or significant laboratory finding that makes the patient undesirable to participate in the study
  • 23. Use of strong inducers of within 14 days of half-lives (whichever is longer) prior to study day 1
  • 24. Use of proton pump inhibitors within 14 days to study day
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    Experimental: Induction treatment + Post-Induction Phase

    Patients enrolled in the study will receive AMG510 (Sotorasib) 960mg once daily for 2 cycles (Q4W) in the induction phase and AMG510 (Sotorasib) 960 mg once daily (Q4W) in the treatment postinduction phase. Treatment post-induction phase only for patients with SD, PR or CR after induction treatment. This treatment will be administered until progression disease (PD), unacceptable toxicity, patient or physician's decision to discontinue or death.

    Drug: Sotorasib

Interventions

  • AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.

    Also known as: AMG510

06

What researchers measure

Primary outcomes

  1. Efficacy of the treatment in terms of the Progression Free Survival (PFS)

    PFS defined as the length of time from the date of end of post-induction treatment to the date of the first documented progression of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: From the date of first dose of induction treatment until 6 months

Secondary outcomes

  1. Overall response rate (ORR) of AMG510 (Sotorasib)

    Overall response will be assessed per RECIST v1.1 criterion. ORR is defined as the proportion of patients who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity.

    Time frame: From the date of the end of treatment until 12 months and 24 months

  2. Overall Survival (OS) rate of treatment with AMG510 (Sotorasib)

    OS defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.

    Time frame: From the date of the start of treatment until 12 and 24 months

  3. Detect and collect the sites of first failure

    Sites of the first failure defined as the first site of the body of documented relapse or progression of the lung cancer disease after a period of improvement.

    Time frame: From the date of the start of treatment until the date of last follow up, assessed up to 24 months

  4. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Occurrence and severity of adverse events, with severity determined by NCI CTCAE v5.0 criteria.

    Time frame: From the subject written informed consent signature to 30 days from last dose of treatment.

07

Study locations

20 of 20 sites recruiting
  • Hospital General Universitario de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • Bartomeu Massuti, MD · Contact
    • Bartomeu Massuti, MD · Principal investigator
  • ICO Badalona, Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Enric Carcereny, MD · Contact
    • Enric Carcereny, MD · Principal investigator
  • Hospital Universitari Quiron Dexeus
    Barcelona, Barcelona 08028, Spain
    Recruiting
    • Maria González, MD · Contact
    • Maria González, MD · Principal investigator
  • Hospital Universitari Vall d' Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Patricia Iranzo, MD · Contact
    • Patricia Iranzo, MD · Principal investigator
  • Hospital Parc Taulí
    Barcelona, Barcelona 08208, Spain
    Recruiting
    • Julia Giner, MD · Contact
    • Julia Giner, MD · Principal investigator
  • Hospital De Basurto
    Bilbao, Bilbao 48013, Spain
    Recruiting
    • Mª Ángeles Sala, MD · Contact
    • Mª Ángeles Sala, MD · Principal investigator
  • ICO Girona, Hospital Josep Trueta
    Girona, Girona 17007, Spain
    Recruiting
    • Elia Sais, MD · Contact
    • Elia Sais, MD · Principal investigator
  • Hospital Clínico San Cecilio De Granada
    Granada, Granada 18016, Spain
    Recruiting
    • Silvia Sequero, MD · Contact
    • Silvia Sequero, MD · Principal investigator
  • Complejo Hospitalario De Jaén
    Jaén, Jaén 23007, Spain
    Recruiting
    • Ana Laura Ortega, MD · Contact
    • Ana Laura Ortega, MD · Principal investigator
  • Hospitalario Universitario A Coruña
    A Coruña, La Coruña 15006, Spain
    Recruiting
    • Rosario García Campelo, MD · Contact
    • Rosario García Campelo, MD · Principal investigator
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo 27003, Spain
    Recruiting
    • Sergio Vázquez, MD · Contact
    • Sergio Vázquez, MD · Principal investigator
  • Hospital Universitario Severo Ochoa
    Leganés, Madrid 28911, Spain
    Recruiting
    • Ana López, MD · Contact
    • Ana López, MD · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Carlos Aguado, MD · Contact
    • Carlos Aguado, MD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
    Recruiting
    • Manuel Dómine, MD · Contact
    • Manuel Dómine, MD · Principal investigator
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Mariano Provencio, MD · Contact
    • Mariano Provencio, MD · Principal investigator
  • Hospital de Son Espases
    Palma de Mallorca, Mallorca 07120, Spain
    Recruiting
    • Aitor Azkárate Martínez, MD · Contact
    • Aitor Azkárate Martínez, MD · Principal investigator
  • Hospital Universitari Son Llatzer
    Palma de Mallorca, Palma de Mallorca 07198, Spain
    Recruiting
    • Francisco Javier Garcia, MD · Contact
    • Francisco Javier Garcia, MD · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, Sevilla 41013, Spain
    Recruiting
    • Reyes Bernabé, MD · Contact
    • Reyes Bernabé, MD · Principal investigator
  • Hospital General Universitario De Valencia
    Valencia, Valencia 46014, Spain
    Recruiting
    • Paula Espinosa, MD · Contact
    • Paula Espinosa, MD · Principal investigator
  • Hospital Universitario La Fe
    Valencia, Valencia 46026, Spain
    Recruiting
    • Oscar Juan-Vidal, MD · Contact
    • Oscar Juan-Vidal, MD · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2027, 69 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 69 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 31, 2022
StartActual
Mar 21, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05398094
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Mar 21, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Eva Pereira
Contact
gecp@gecp.org
934302006
Mariano Provencio, MD
study chair · Fundación GECP President

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion